Siliq (brodalumab) / AstraZeneca, Bausch Health, LEO Pharma, Kyowa Kirin, Amgen - LARVOL DELTA

Risk of Incident Inflammatory Bowel Disease Among Patients With Psoriasis Treated With IL-17 Versus TNF Inhibitors: A Propensity-Matched TriNetX Study (ACG 2026) - "Adults (â¥18 years) with psoriasis initiating an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab, or bimekizumab) were compared with those starting a TNF inhibitor (adalimumab, infliximab, golimumab, or certolizumab pegol) after diagnosis...Cohorts underwent 1:1 propensity score matching on age, sex, race, ethnicity, diabetes, obesity, celiac disease, tobacco use, psoriatic arthritis (a disease-severity marker), and NSAID, antimicrobial, glucocorticoid, and methotrexate use, yielding 20,547 patients per cohort... After excluding prior IBD, 20,368 IL-17 and 18,987 TNF inhibitor users remained. At 1 year, incident IBD occurred in 46 IL-17 versus 79 TNF users (0.2% vs 0.4%), with significantly lower risk for IL-17 (relative risk [RR] 0.54, 95% CI 0.38â0.78; hazard ratio [HR] 0.56, 95% CI 0.39â0.81; log-rank p=0.002). At 3 years, IBD occurred in 85 versus 161 patients (0.4% vs 0.8%; RR 0.49, 95% CI 0.38â0.64; HR 0.54, 95% CI 0.42â0.70;..."

Clinical • Celiac Disease • Crohn's disease • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nicotine Addiction • Obesity • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review. (PubMed, J Dermatolog Treat) - "In real-world studies of patients with treatment failure on anti-IL-17 agents (secukinumab and/or ixekizumab), brodalumab achieved PASI 75, PASI 90, and PASI 100 in 47.8%-81.7%, 40.0%-58.9%, and 28.0%-50.0% of patients, respectively, after 12-16 weeks of treatment. Studies with longer-term follow-up have suggested that responses to brodalumab are durable in biologic-experienced patients. Literature evaluated in this narrative review positions brodalumab as a rational, safe, and effective treatment option for adults with moderate to severe plaque psoriasis who have an inadequate response/loss of an initial response to their existing biologic agent."

Journal • Review • Dermatology • Immunology • Oncology • Psoriasis • IL12A • IL23A • TNFA

Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials. (PubMed, Front Immunol) - "For palmoplantar psoriasis, secukinumab ranked highest (SUCRA = 79.7%), followed by bimekizumab (72.2%) and ustekinumab (69.7%)...For scalp psoriasis, brodalumab (87.7%) and ixekizumab (86.9%) ranked highest, followed by bimekizumab (69.0%) and guselkumab (65.1%); the brodalumab estimate relied on a single contributing study...Bimekizumab and ixekizumab showed consistently favorable rankings across sites, but treatment selection should consider certainty of evidence, sensitivity analyses, long-term response, and patient-level factors. https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251271255."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Brodalumab and Secukinumab in the treatment of Patients with Moderate-to-Severe Plaque Psoriasis Weighing 90 kg or More (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial. (PubMed, Lancet Reg Health Eur) - P4 | "Patients with stable low disease activity on registered dosages of IL17i (secukinumab, ixekizumab, bimekizumab, brodalumab) or IL23i (guselkumab, risankizumab, tildrakizumab) were eligible. Disease-activity guided, stepwise interval prolongation of IL17i and IL23i in patients with controlled psoriasis is an effective and safe strategy to reduce unnecessary exposure to these expensive drugs. ZonMw (the Netherlands Organization for Health Research and Development), KCE Trials (the Belgian Health Care Knowledge Centre)."

Head-to-Head • Journal • Dermatology • Immunology • Psoriasis • IL17A

Pro-inflammatory cytokine reduction in psoriasis patients treated withtildrakizumab, brodalumab and methotrexate: A prospective study. (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Modulation of leukemia inhibitory factor (LIF) pathway in patients treated with tildrakizumab, brodalumab and methotrexate: A potential marker of cardiovascular inflammation improvement under tildrakizumab treatment. (EADV 2026) - No abstract available

Clinical • Hematological Malignancies • Leukemia • LIF

Real-world effectiveness of brodalumab in overweight and obese psoriasis patients: a French, ambispective, multicenter cohort. (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Obesity • Psoriasis

Brodalumab demonstrates rapid effectiveness in patients with moderate-to-severe plaque psoriasis: short-term results from the Greek REALITY-1 non-interventional study (EADV 2026) - No abstract available

Clinical • Observational data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Systemic Immune-Inflammation Index (SII) and systemic inflammation response index (SIRI) trend in psoriatic patients treated with brodalumab: a real-life pilot study (EADV 2026) - No abstract available

Clinical • Immunology • Inflammation • Systemic Inflammatory Response Syndrome

Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis). (PubMed, Dermatol Ther (Heidelb)) - "Brodalumab provided rapid, deep, and sustained disease control over 52 weeks. Patient-level cumulative outcomes may complement conventional PASI response rates by capturing the overall longitudinal treatment benefit."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Comparison of short-term adverse reactions of small molecule inhibitors and biologics in the treatment of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network Meta-analysis. (PubMed, Int Immunopharmacol) - "Stratified analyses showed that in PP, adalimumab 40 mg had a lower risk of any AEs (SUCRA: 73.93%) and infections (SUCRA: 79.16%), whereas risankizumab 150 mg had a lower risk of serious AEs (SUCRA: 91.10%). In PPP, guselkumab 100 mg had a lower risk of any AEs (SUCRA: 85.46%) and infections (SUCRA: 81.62%), whereas brodalumab 210 mg had a lower risk of serious AEs (SUCRA: 68.40%). Based on currently available short-term RCT evidence, guselkumab 100 mg had a lower risk of any AEs whereas adalimumab 40 mg ranked more favorably for serious AEs and infections. Given short follow-up durations, few relevant events, and wide credible intervals, all comparative findings should be interpreted with caution."

Journal • Retrospective data • Review • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis

Speed of Response in Biologic Treatments for Moderate-to-Severe Plaque Psoriasis: Bayesian Network Meta-Analysis. (PubMed, J Drugs Dermatol) - "IL-17 inhibitors, specifically bimekizumab, brodalumab, and ixekizumab, had a higher percentage of patients (measured as absolute difference in this study), achieving PASI 75, PASI 90, and PASI 100 at week 4 and week 8. However, there was no significant difference in absolute difference for the same endpoints and time points for patients treated with brodalumab, bimekizumab, and ixekizumab. IL-23 inhibitors, while effective, exhibited a slower onset; TNF-alpha inhibitors, except infliximab, generally showed slower responses. Indirect comparisons and differences in study design and populations may limit the generalizability of the results. &nbsp."

Clinical • Journal • Retrospective data • Dermatology • Immunology • Oncology • Psoriasis • IL17A • IL23A

(Pr)SILIQ (brodalumab injection) Now Reimbursed Under Alberta's Public Drug Plan, Improving Access for Eligible Patients with Moderate to Severe Plaque Psoriasis (PRNewswire)

Reimbursement • Immunology • Plaque Psoriasis

Improvement of interstitial lung disease during brodalumab treatment in a patient with psoriasis and systemic immune-mediated inflammation. (PubMed, Eur J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Inflammation • Interstitial Lung Disease • Psoriasis • Pulmonary Disease • Respiratory Diseases

Alisol A 23,24-diacetate improves LPS-induced acute lung injury through the IL-17A/NF-κB signaling pathway. (PubMed, Chin Med) - "AAD improves LPS-induced ALI through the IL-17A/NF-κB signaling pathway."

Journal • Acute Lung Injury • Immunology • Respiratory Diseases • IL17A

IL-17A Restrains Antiviral Immunity to Promote Chikungunya Virus Infection and Pathogenesis in the Heart. (PubMed, bioRxiv) - "Interestingly, blockade of IL-17RA with an FDA-approved monoclonal antibody for plaque psoriasis, Brodalumab, drastically increased type I interferon production and reduced viral replication in both human cardiac fibroblasts and human embryonic kidney 293 (HEK 293) cells...Importantly, therapeutic inhibition of IL-17A signaling after infection remained effective in reducing viral replication in both cardiac tissue and circulation and mitigating cardiac damage. These findings reveal a critical role for the IL-17A/IL-17RA axis in linking antiviral immunity to CHIKV-induced cardiovascular disease and identify a potential translatable therapeutic target for CHIKV-caused cardiac complications."

Journal • Cardiovascular • Chikungunya • Dermatology • Heart Failure • Immunology • Infectious Disease • Inflammation • Psoriasis • IFNAR2 • IFNG • IL17A • IL17RA • IL1B • TNFA

IL-17 Receptor inhibition with brodalumab limits experimental periodontitis. (PubMed, J Transl Med) - "Local gingival administration of brodalumab attenuates IL-17-associated inflammatory responses and protects against alveolar bone loss in experimental periodontitis. Our findings support IL-17R blockade as a promising host-modulatory strategy that could serve as an adjunct to conventional periodontal care to limit periodontal tissue destruction."

Journal • Dental Disorders • Inflammation • Osteoporosis • Periodontitis • CD4 • IL17A

Efficacy and safety of interleukin inhibitors in the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. (PubMed, Front Med (Lausanne)) - "The meta-analysis results showed that several regimens, including Guselkumab 200 mg, Secukinumab 300 mg, and Brodalumab 210 mg, ranked highly for PASI 75 and PASI 90 at specific follow-up time points; however, ranking patterns varied across outcomes and follow-up durations. Additionally, Tildrakizumab 100 mg and Tildrakizumab 200 mg showed high SUCRA values for achieving cleared or almost cleared skin and reducing the Dermatology Life Quality Index (DLQI) score at most follow-up time points...Treatment rankings should be interpreted within each outcome and follow-up time point, together with effect estimates, safety profiles, and the amount of supporting evidence. https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024584441."

Journal • Retrospective data • Review • Dermatology • Immunology • Inflammation • Psoriasis • IL17A • IL23A

Exploratory MRI and Clinical Marker Analysis of Pustulotic Arthro-Osteitis Disease Activity From a Phase 3 Brodalumab Trial. (PubMed, J Dermatol) - P3 | "Further external validation is warranted, and additional clinical indicators are needed to predict disease activity. Trial Registration: NCT04061252, UMIN000055398."

Journal • P3 data • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Pain • Psoriasis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study. (PubMed, Dermatol Ther (Heidelb)) - "These findings provide real-world evidence of the sustained use of IL-17 inhibitors in Japanese patients with PsV. Persistence showed no significant association with patient characteristics such as age, comorbidities, and concomitant medications."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A

Beyond the Usual Targets: A Case Report of Overcoming IL-23 and IL-17A Biologic Nonresponse in Palmoplantar Psoriasis With Brodalumab. (PubMed, J Clin Aesthet Dermatol) - "This case highlights the potential role of IL-17RA blockade in localized, treatment-resistant psoriasis and supports further investigation into its use for palmoplantar disease."

Journal • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis • IL17A • IL17RA • IL23A

Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis. (PubMed, Dermatol Res Pract) - "We retrospectively reviewed 173 treatment courses with IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab) and the IL-23 inhibitor guselkumab, documenting loading regimens, maintenance dosing, efficacy to Week 52, and switching events. Erythrodermic psoriasis and higher baseline disease severity predicted switching, whereas incomplete loading doses and dose reductions did not. In conclusion, full loading and standard maintenance regimens facilitate early treatment response, while dose reduction in carefully selected patients can sustain long-term disease control without increasing the risk of switching."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A • IL23A

IL-17 Signaling Inhibitors in Localized Scleroderma: A Single-Center Case Series of Nine Patients. (PubMed, J Dermatol) - "Here, we present nine patients with LSc treated with IL-17A or IL-17 receptor A inhibitors at our institution (ixekizumab, secukinumab, or brodalumab). One patient developed pustulotic arthro-osteitis during brodalumab treatment, possibly representing a paradoxical reaction; no other major adverse events were observed. Although these uncontrolled retrospective data do not establish efficacy, they suggest that IL-17 pathway inhibition merits further study in selected patients with refractory LSc."

Journal • Fibrosis • Immunology • Inflammation • Scleroderma • Systemic Sclerosis • IL17A • IL17RA